Jun Liu

Aucentra Therapeutics Pty Ltd. is an Australian biotech company that develops advanced anti-cancer drugs. The private company is based in Adelaide, Australia. Established in 2017, the company focuses on breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, including leukaemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer. The company's pipeline consists of first-in-class or novel kinase inhibitors in pre-clinical and clinical stage development, with a particular focus on targeting cyclin dependent kinases (cdks), known for their over-expression in cancer cells. The company was founded in 2017 by Shudong Wang, and the CEO is Joe Bayer.

Aucentra Therapeutics Pty Ltd. is an Australian biotech company that develops advanced anti-cancer drugs. The private company is based in Adelaide, Australia. Established in 2017, the company focuses on breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, including leukaemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer. The company's pipeline consists of first-in-class or novel kinase inhibitors in pre-clinical and clinical stage development, with a particular focus on targeting cyclin dependent kinases (cdks), known for their over-expression in cancer cells. The company was founded in 2017 by Shudong Wang, and the CEO is Joe Bayer.

Aucentra Therapeutics Pty Ltd. is an Australian biotech company that develops advanced anti-cancer drugs. The private company is based in Adelaide, Australia. Established in 2017, the company focuses on breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, including leukaemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer. The company's pipeline consists of first-in-class or novel kinase inhibitors in pre-clinical and clinical stage development, with a particular focus on targeting cyclin dependent kinases (cdks), known for their over-expression in cancer cells. The company was founded in 2017 by Shudong Wang, and the CEO is Joe Bayer.